ITGAV and urinary bladder cancer: Inhibition of αv integrin might also have therapeutic potential in bladder cancer, since ITGAV is significantly overexpressed in bladder tumors (46%) compared to normal urothelium (13%) and a trend is observed of stage and grade-dependent increase in ITGAV expression [33].